McGlone Suttner Wealth Management Inc. Has $271,000 Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

McGlone Suttner Wealth Management Inc. increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,936 shares of the biopharmaceutical company’s stock after acquiring an additional 195 shares during the quarter. McGlone Suttner Wealth Management Inc.’s holdings in Gilead Sciences were worth $271,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in GILD. nVerses Capital LLC bought a new position in shares of Gilead Sciences in the 3rd quarter valued at about $25,000. Valued Wealth Advisors LLC lifted its holdings in Gilead Sciences by 101.9% in the third quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 161 shares during the period. Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences during the 4th quarter worth $29,000. Strategic Investment Solutions Inc. IL bought a new stake in Gilead Sciences in the second quarter valued at about $33,000. Finally, Quarry LP acquired a new stake in shares of Gilead Sciences in the 2nd quarter valued at approximately $43,000. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD opened at $92.92 on Friday. The firm has a market capitalization of $115.80 billion, a PE ratio of 1,032.44, a PEG ratio of 1.31 and a beta of 0.18. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company’s 50-day moving average is $91.63 and its 200-day moving average is $84.63. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. The company had revenue of $7.55 billion during the quarter, compared to analysts’ expectations of $7.01 billion. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The business’s revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.29 earnings per share. Equities analysts forecast that Gilead Sciences, Inc. will post 4.36 EPS for the current year.

Gilead Sciences Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Monday, December 30th. Stockholders of record on Friday, December 13th were issued a dividend of $0.77 per share. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.31%. The ex-dividend date was Friday, December 13th. Gilead Sciences’s dividend payout ratio is currently 3,422.22%.

Insider Activity

In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Jeffrey Bluestone sold 6,788 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total transaction of $620,355.32. Following the transaction, the director now directly owns 8,920 shares in the company, valued at $815,198.80. This represents a 43.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 456,234 shares of company stock valued at $42,130,461. 0.16% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Morgan Stanley raised Gilead Sciences from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $87.00 to $113.00 in a research note on Friday, January 10th. Citigroup initiated coverage on shares of Gilead Sciences in a research note on Thursday, November 14th. They issued a “buy” rating and a $125.00 target price for the company. Truist Financial lifted their price target on Gilead Sciences from $83.00 to $97.00 and gave the company a “hold” rating in a research note on Friday, November 8th. BMO Capital Markets upped their price objective on Gilead Sciences from $94.00 to $102.00 and gave the stock an “outperform” rating in a research report on Thursday, November 7th. Finally, Oppenheimer lifted their target price on Gilead Sciences from $105.00 to $115.00 and gave the company an “outperform” rating in a research report on Tuesday, December 10th. Eleven analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and four have assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $97.96.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.